We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,358
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IIN
2776
DELISTED
IntriCon Corporation
IIN
| $181K | ﹤0.01% |
10,048
+14
| +0.1% | +$268 |
|
2777
DHI Group
DHX
$179M
| $180K | ﹤0.01% |
59,964
+1,400
| +2% | +$4.76K |
|
2778
Aldeyra Therapeutics
ALDX
$93.5M
| $179K | ﹤0.01% |
30,784
+143
| +0.5% | +$826 |
|
|
BWIN
2779
Baldwin Insurance Group
BWIN
$2.79B
| $179K | ﹤0.01% |
+11,159
| New | +$178K |
|
2780
Savara
SVRA
$1.11B
| $177K | ﹤0.01% |
39,576
-704
| -2% | -$847 |
|
2781
LifeVantage
LFVN
$86.2M
| $176K | ﹤0.01% |
11,257
+315
| +3% | +$4.63K |
|
2782
Target Hospitality
TH
$1.59B
| $175K | ﹤0.01% |
34,939
+463
| +1% | +$2.43K |
|
|
SDRL
2783
DELISTED
Seadrill Limited Common Stock
SDRL
| $175K | ﹤0.01% |
68,846
+729
| +1% | +$1.21K |
|
2784
Flotek Industries
FTK
$1.02B
| $174K | ﹤0.01% |
14,490
+185
| +1% | +$2.13K |
|
2785
Abeona Therapeutics
ABEO
$389M
| $172K | ﹤0.01% |
2,101
+67
| +3% | +$4.73K |
|
|
USX
2786
DELISTED
U.S. Xpress Enterprises, Inc. Class A Common Stock
USX
| $171K | ﹤0.01% |
33,964
-154
| -0.5% | -$750 |
|
2787
American Superconductor
AMSC
$1.62B
| $170K | ﹤0.01% |
21,654
+324
| +2% | +$2.61K |
|
2788
Capital Bancorp
CBNK
$618M
| $169K | ﹤0.01% |
11,342
+234
| +2% | +$3.32K |
|
|
AKTS
2789
DELISTED
Akoustis Technologies Inc
AKTS
| $167K | ﹤0.01% |
20,871
+767
| +4% | +$5.99K |
|
|
XXII
2790
22nd Century Group
XXII
$1.52M
| – | – |
0
| – | – |
|
|
CBAY
2791
DELISTED
Cymabay Therapeutics
CBAY
| $166K | ﹤0.01% |
84,887
-118
| -0.1% | -$443 |
|
2792
Noodles & Co
NDLS
$106M
| $165K | ﹤0.01% |
3,717
+36
| +1% | +$1.59K |
|
|
AGNT
2793
AGNT Inc
AGNT
$693M
| $164K | ﹤0.01% |
28,874
+5,642
| +24% | +$28K |
|
|
PVBC
2794
DELISTED
Provident Bancorp
PVBC
| $164K | ﹤0.01% |
+13,169
| New | +$155K |
|
|
CASA
2795
DELISTED
Casa Systems, Inc. Common Stock
CASA
| $164K | ﹤0.01% |
40,015
+794
| +2% | +$3.79K |
|
|
GFN
2796
DELISTED
General Finance Corporation
GFN
| $164K | ﹤0.01% |
14,823
-214
| -1% | -$2.11K |
|
2797
Escalade
ESCA
$303M
| $163K | ﹤0.01% |
16,599
-599
| -3% | -$6.49K |
|
2798
Ascent Industries
ACNT
$139M
| $161K | ﹤0.01% |
12,487
-102
| -0.8% | -$1.42K |
|
2799
Lineage Cell Therapeutics
LCTX
$279M
| $161K | ﹤0.01% |
180,344
+143
| +0.1% | +$119 |
|
2800
Medallion Financial
MFIN
$251M
| $161K | ﹤0.01% |
22,180
+507
| +2% | +$3.32K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.